ArticleACS applied materials & interfaces2018
Cardiac Stem Cell Patch Integrated with Microengineered Blood Vessels Promotes Cardiomyocyte Proliferation and Neovascularization after Acute Myocardial Infarction.
Article in ACS applied materials & interfaces, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 86 citations in OpenAlex.
- Inhalable bioadhesive barrier for lung protection and clearance of fine particulate matter.Bioactive materials · 2026Article
- Bioenzymatic single-cell microencapsulation for enhanced stem Cell therapy.Bioactive materials · 2026Article
- Avenues for optimization of cardiac therapeutics by minimally invasive delivery.Acta biomaterialia · 2026Review
- Key Steps in Murine Cardiac Engineering Validation: How Does It Affect the Efficiency of Cardiac Devices?BioMed research international · 2026Review
- Stromal-platelet membrane-inspired nanoparticles (SPIN) for targeted heart repair.Bioactive materials · 2025Article
- Stem cells derived exosome laden oxygen generating hydrogel composites with good electrical conductivity for the tissue-repairing process of post-myocardial infarction.Journal of nanobiotechnology · 2025Article
- Hydrogels for Cardiac Tissue Regeneration: Current and Future Developments.International journal of molecular sciences · 2025Review
- Application and progress of 3D printed biomaterials in osteoporosis.Frontiers in bioengineering and biotechnology · 2025Review
- Engineering a robust and anisotropic cardiac-specific extracellular matrix scaffold for cardiac patch tissue engineering.Matrix biology plus · 2024Article
- Applications of extraembryonic tissue-derived cells in vascular tissue regeneration.Stem cell research & therapy · 2024Review
- Advanced Cardiac Patches for the Treatment of Myocardial Infarction.Circulation · 2024Review
- Article
- Dual human iPSC-derived cardiac lineage cell-seeding extracellular matrix patches promote regeneration and long-term repair of infarcted hearts.Bioactive materials · 2023Article
- Integrated Manufacturing of Suspended and Aligned Nanofibrous Scaffold for Structural Maturation and Synchronous Contraction of HiPSC-Derived Cardiomyocytes.Bioengineering (Basel, Switzerland) · 2023Article
- Review
- lncRNA-TCONS_00008552 expression in patients with pulmonary arterial hypertension due to congenital heart disease.PloS one · 2023Article
- Cardiac Mesenchymal Stem Cell-like Cells Derived from a Young Patient with Bicuspid Aortic Valve Disease Have a Prematurely Aged Phenotype.Biomedicines · 2022Article
- Advanced Drug Delivery Micro- and Nanosystems for Cardiovascular Diseases.Molecules (Basel, Switzerland) · 2022Review
- Microfluidics Fabrication of Micrometer-Sized Hydrogels with Precisely Controlled Geometries for Biomedical Applications.Advanced healthcare materials · 2022Review
- Exosomes as a messager to regulate the crosstalk between macrophages and cardiomyocytes under hypoxia conditions.Journal of cellular and molecular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
Cardiac stem cell (CSC) therapy has shown preclinical and clinical evidence for ischemic heart repair but is limited by low cellular engraftment and survival after transplantation. Previous versions of the cardiac patch strategy improve stem cell engraftment and encourage repair of cardiac tissue. However, cardiac patches that can enhance cardiomyogenesis and angiogenesis at the injured site remain elusive. Therapies that target cardiomyocyte proliferation and new blood vessel formation hold great potential for the protection against acute myocardial infarction (MI). Here, we report a new strategy for creating a vascularized cardiac patch in a facile and modular fashion by leveraging microfluidic hydrodynamic focusing to construct the biomimetic microvessels (BMVs) that include human umbilical vein endothelial cells (HUVECs) lining the luminal surface and then encapsulating the BMVs in a fibrin gel spiked with human CSCs. We show that the endothelialized BMVs mimicked the natural architecture and function of capillaries and that the resultant vascularized cardiac patch (BMV-CSC patch) exhibited equivalent release of paracrine factors compared to those of coculture of genuine human CSCs and HUVECs after 7 days of in vitro culture. In a rat model of acute MI, the BMV-CSC patch therapy induced profound mitotic activities of cardiomyocytes in the peri-infarct region 4 weeks post-treatment. A significant increase in myocardial capillary density was noted in the infarcted hearts that received BMV-CSC patch treatment compared to the infarcted hearts treated with conventional CSC patches. The striking therapeutic benefits and the fast and facile fabrication of the BMV-CSC patch make it promising for practical applications. Our findings suggest that the BMV-CSC patch strategy may open up new possibilities for the treatment of ischemic heart injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.